p53-induced apoptosis in the human T-ALL cell line CCRF-CEM

Oncogene. 1997 Nov 13;15(20):2429-37. doi: 10.1038/sj.onc.1201399.

Abstract

The tumor suppressor p53 has been implicated in apoptosis induction and is mutated in human T-ALL CCRF-CEM cells. To investigate possible consequences of wild-type p53 loss, we reconstituted CEM-C7H2, a subclone of CCRF-CEM, with a temperature-sensitive p53 allele (p53ts). Stably transfected lines expressed high levels of p53ts and shift to the permissive temperature (32 degrees C) caused rapid induction of p53-regulated genes, such as p21(CIP1/WAF1), mdm-2 and bax. This was followed by extensive apoptosis within 24 h to 36 h, supporting the notion that mutational p53 inactivation contributed to the malignant phenotype. p53-dependent apoptosis was preceded by digestion of poly(ADP-ribose) polymerase, a typical target of interleukin-1beta-converting enzyme (ICE)-like proteases/caspases, and was markedly resistant to the ICE/caspase-1 and FLICE/caspase-8 inhibitor acetyl-Tyr-Val-Ala-Asp.chloromethylketone (YVAD), but sensitive to the CPP32/caspase-3 inhibitor benzyloxycarbonyl-Asp-Glu-Val-Asp.fluoromethylketone (DEVD) and benzyloxycarbonyl-Val-Ala-Asp.fluoromethylketone (zVAD), a caspase inhibitor with broader specificity. This indicated an essential involvement of caspases, but argued against a significant role of ICE/caspase-1 or FLICE/caspase-8. Actinomycin D or cycloheximide prevented cell death, suggesting that, in this system, p53-induced apoptosis depends upon macromolecule biosynthesis. Introduction of functional p53 into CEM cells enhanced their sensitivity to the DNA-damaging agent doxorubicin, but not to the tubulin-active compound vincristine. Thus, mutational p53 inactivation in ALL might entail relative resistance to DNA-damaging, but not to tubulin-destabilizing, chemotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects
  • Apoptosis / physiology*
  • Caspase 1
  • Caspase 8
  • Caspase 9
  • Caspases*
  • Cycloheximide / pharmacology
  • Cysteine Endopeptidases / physiology*
  • Cysteine Proteinase Inhibitors / pharmacology
  • Dactinomycin / pharmacology
  • Doxorubicin / pharmacology
  • Drug Resistance, Neoplasm
  • Enzyme Inhibitors / pharmacology
  • Gene Expression Regulation, Leukemic* / drug effects
  • Genes, p53
  • Heterozygote
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell / pathology*
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / physiology*
  • Nucleic Acid Synthesis Inhibitors / pharmacology
  • Phenotype
  • Poly(ADP-ribose) Polymerases / metabolism
  • Protein Synthesis Inhibitors / pharmacology
  • Recombinant Fusion Proteins / physiology
  • Temperature
  • Transfection
  • Tubulin / metabolism
  • Tumor Cells, Cultured / drug effects
  • Tumor Suppressor Protein p53 / physiology*
  • Vincristine / pharmacology

Substances

  • Antineoplastic Agents
  • Cysteine Proteinase Inhibitors
  • Enzyme Inhibitors
  • Neoplasm Proteins
  • Nucleic Acid Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • Recombinant Fusion Proteins
  • Tubulin
  • Tumor Suppressor Protein p53
  • Dactinomycin
  • Vincristine
  • Doxorubicin
  • Cycloheximide
  • Poly(ADP-ribose) Polymerases
  • CASP8 protein, human
  • CASP9 protein, human
  • Caspase 8
  • Caspase 9
  • Caspases
  • Cysteine Endopeptidases
  • Caspase 1